GT Biopharma (GTBP) Operating Expenses (2010 - 2026)
GT Biopharma (GTBP) posted quarterly Operating Expenses of $2.0 million for Q1 2026, up 307.17% year-over-year from $488000.0 in Q1 2025, and down 46.03% quarter-over-quarter from $3.7 million in Q4 2025.
GT Biopharma (GTBP) Operating Expenses (2010 - 2026) Analysis & Trends
GT Biopharma (GTBP) has reported Operating Expenses for 17 consecutive years, with $2.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Expenses rose 307.17% year-over-year to $2.0 million; the TTM figure through Mar 2026 stood at $8.3 million (up 147.11% YoY), while the FY2025 annual figure was $6.8 million, up 49.93% from the prior year.
- Operating Expenses slipped to $2.0 million in Q1 2026 per GTBP's latest filing, from $3.7 million in the prior quarter.
- Across five years, Operating Expenses topped out at $7.0 million in Q3 2022 and bottomed at -$645000.0 in Q4 2024.
- Historically, Operating Expenses has averaged $2.8 million across 5 years, with a median of $3.0 million in 2022.
- Annual changes were most pronounced in 2024 — Operating Expenses plunged 120.36% — and 2025, when it soared 670.85%.
- GT Biopharma's Operating Expenses stood at $5.8 million in 2022, then tumbled by 45.17% to $3.2 million in 2023, then slumped by 120.36% to -$645000.0 in 2024, then jumped by 670.85% to $3.7 million in 2025, then slumped by 46.03% to $2.0 million in 2026.
- Business Quant data shows GTBP's Operating Expenses at $2.0 million in Q1 2026, $3.7 million in Q4 2025, and $1.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | GT Biopharma | 8.38 Mn | 8.38 Mn | - | 1.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.99 Mn |
| Dec 31, 2025 | 3.68 Mn |
| Sep 30, 2025 | 1.94 Mn |
| Jun 30, 2025 | 734,000.00 |
| Mar 31, 2025 | 488,000.00 |
| Dec 31, 2024 | -645,000.00 |
| Sep 30, 2024 | 1.92 Mn |
| Jun 30, 2024 | 1.62 Mn |
| Mar 31, 2024 | 1.66 Mn |
| Dec 31, 2023 | 3.17 Mn |
| Sep 30, 2023 | 3.12 Mn |
| Jun 30, 2023 | 3.62 Mn |
| Mar 31, 2023 | 3.67 Mn |
| Dec 31, 2022 | 5.78 Mn |
| Sep 30, 2022 | 7.02 Mn |
| Jun 30, 2022 | 3.01 Mn |
| Mar 31, 2022 | 5.44 Mn |
| Dec 31, 2021 | 18.18 Mn |
| Sep 30, 2021 | 5.95 Mn |
| Jun 30, 2021 | 4.38 Mn |